C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.
复制标题
DOI：
10.1054/bjoc.2000.1522
复制
发表时间：
2000-12
影响因子：
8.8
通讯作者：
Trock BJ
中科院分区：
文献类型：
--
作者：
Deming SL;Nass SJ;Dickson RB;Trock BJ
基础研究的数据表明，原癌基因c-myc的扩增在乳腺癌发病机制中很重要，但其在人类研究中的扩增频率和预后相关性一直不一致。为了阐明c-myc扩增在乳腺癌中的临床意义，我们进行了全面的文献检索和荟萃分析，其中29项研究进行了评估。乳腺肿瘤中c-myc扩增的加权平均频率为15.7%（95%CI = 12.5-18.8%），尽管个体研究中的估计值显示出显著的异质性，P<0.0001。 C-myc扩增与肿瘤分级（RR = 1.61）、淋巴结转移（RR = 1.24）、孕酮受体阴性（RR = 1.27）和绝经后状态（RR = 0.82）有显著但微弱的相关性。扩增与复发和死亡风险显著相关，合并估计RR = 2.05（95%CI = 1.51-2.78）和RR = 1.74（95%CI = 1.27-2.39）。这种影响似乎不仅仅是其他预后因素的替代。这些结果表明，c-myc扩增是相对常见的乳腺癌，并可能提供独立的预后信息。需要更严格的研究与一致的方法来验证这种关联，并研究其作为特异性治疗反应的分子预测因子的潜力。© 2000年癌症研究运动http://www.bjcancer.com
Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P< 0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.com
登录
查看更多内容
DOI：
10.1073/pnas.83.13.4834
发表时间：
1986-07-01
影响因子：
11.1
作者：
ESCOT, C;THEILLET, C;CALLAHAN, R
通讯作者：
CALLAHAN, R
影响因子：
8.4
作者：
BERNS, EMJJ;KLIJN, JGM;FOEKENS, JA
通讯作者：
FOEKENS, JA
影响因子：
6.4
作者：
CONTEGIACOMO, A;PIZZI, C;MARIANICOSTANTINI, R
通讯作者：
MARIANICOSTANTINI, R
DOI：
10.1002/cyto.990210106
发表时间：
1995-09-01
期刊：
CYTOMETRY
影响因子：
--
作者：
JANOCKO, LE;LUCKE, JF;SHACKNEY, SE
通讯作者：
SHACKNEY, SE
影响因子：
6.4
作者：
BORG, A;BALDETORP, B;SIGURDSSON, H
通讯作者：
SIGURDSSON, H